Welcome to our dedicated page for THERIVA BIOLOGICS SEC filings (Ticker: TOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Theriva Biologics, Inc. filings document a Nevada clinical-stage biotechnology issuer with common stock listed on the NYSE American under TOVX. The company’s Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical and regulatory updates for VCN-01, and material-event disclosures tied to its oncology development programs.
Theriva Biologics proxy statements cover stockholder meeting mechanics, governance matters and shareholder approval proposals related to warrant exercises and potential common-stock issuance under NYSE American rules. Other 8-K disclosures record material definitive agreements, including the SYN-020 license arrangement, alongside capital-structure, voting and corporate-update information relevant to the company’s development-stage business.
Theriva Biologics (NYSE: TOVX) has announced a significant at-the-market (ATM) offering through an amended sales agreement with A.G.P./Alliance Global Partners. The company plans to offer up to $2.53 million worth of common stock through this facility.
Key details of the ATM offering include:
- Sales will be conducted through A.G.P./Alliance Global Partners as Sales Agent
- Sales Agent commission rate set at 3.0% of gross sales price per share
- Offering falls under the previously effective S-3 Registration Statement (File No. 333-279077) from September 2024
- Sales will be made through methods qualifying as "at the market offering" under Rule 415(a)(4)
The filing includes legal validation through Parsons Behle & Latimer's opinion on share validity. This offering provides Theriva with flexibility to raise capital as needed, though there's no obligation to sell any specific amount of shares.
Theriva Biologics (TOVX) has filed a prospectus supplement for an at-market offering of up to $2,534,352 worth of common stock through A.G.P./Alliance Global Partners. The offering is made under an Amended and Restated At Market Issuance Sales Agreement from February 2021, with subsequent amendments.
Key financial details:
- Previous sales: ~569,000 shares generating net proceeds of ~$3.6M in 2024
- Current stock price: $0.465 (as of June 17, 2025)
- Public float value: ~$12.9M based on 9,049,241 non-affiliate shares
- Sales agent commission: up to 3.0% of gross sales
The company, following its March 2022 acquisition of VCN Biosciences, focuses on developing cancer therapeutics. Their lead candidate, VCN-01, is an oncolytic adenovirus currently in Phase 2b trials for pancreatic cancer and Phase 1 studies for retinoblastoma and other solid tumors. The offering is limited by the one-third public float rule under Form S-3 requirements.